{"entity":{"id":"paper-promise-innovation-2026","kind":"paper","name":"Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study","aka":[],"tldr":"A Chinese study comparing DNA methylation, DNA mutations and proteins in blood found methylation the strongest signal for nine cancers, with proteins adding some extra cancers.","summary":"PROMISE (NCT04972201) prospectively collected blood from 1,706 participants (866 with one of nine cancers, 840 without), split into training and validation sets. The methylation classifier outperformed mutation-based and protein-based classifiers; 95.0% of cancers detected by mutations were also detected by methylation. Combining methylation and protein features raised sensitivity to 75.1% (69.3 to 80.3) at the same 98.8% specificity, with 73.1% accuracy for the top predicted origin.","asOf":"2026-10-29","links":[{"label":"The Innovation 2026: PROMISE","url":"https://doi.org/10.1016/j.xinn.2025.101076"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/41737326/"},{"label":"ClinicalTrials.gov NCT04972201","url":"https://clinicaltrials.gov/study/NCT04972201"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["mced","cfdna-methylation-testing","proteomics"],"targets":[],"drugs":["overc-mcdbt"],"companies":["burning-rock"],"institutions":[],"pathways":[],"terms":[],"trials":["promise-cams"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"The Innovation","year":2026,"doi":"10.1016/j.xinn.2025.101076","pmid":"41737326","authors":"Duan J, Gao Q, Wang Z, et al.","paperType":"observational","findings":["Methylation outperformed mutations and proteins.","Methylation plus protein: 75.1% sensitivity at 98.8% specificity; top predicted origin correct in 73.1%."],"whatItMeans":"Supports the design choice of most current tests: methylation first, with proteins as an add-on rather than mutations.","caveats":["Case-control; known cancers.","Burning Rock affiliation among authors."],"changedPractice":false,"participants":1706},"route":"/key-papers/paper-promise-innovation-2026/","neighbours":{"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"cfdna-methylation-testing","kind":"technology","name":"Cell-free DNA methylation tests","route":"/technologies/cfdna-methylation-testing/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"},{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/"}],"drug":[{"id":"overc-mcdbt","kind":"drug","name":"OverC Multi-Cancer Detection Blood Test","route":"/drugs/overc-mcdbt/"}],"company":[{"id":"burning-rock","kind":"company","name":"Burning Rock Biotech","route":"/companies/burning-rock/"}],"trial":[{"id":"promise-cams","kind":"trial","name":"PROMISE (pan-cancer liquid biopsy proof of concept, Chinese Academy of Medical Sciences)","route":"/trials/promise-cams/"}]}}